Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthetic pathway and has been exploited as the target for therapy against proliferative and parasitic diseases. In this study, we report the crystal structures of DHODH from Leishmania major, the species of Leishmania associated with zoonotic cutaneous leishmaniasis, in its apo form and in complex with orotate and fumarate molecules. Both orotate and fumarate were found to bind to the same active site and exploit similar interactions, consistent with a ping-pong mechanism described for class 1A DHODHs. Analysis of LmDHODH structures reveals that rearrangements in the conformation of the catalytic loop have direct influence on the dimeric interface. This is the first structural evidence of a relationship between the dimeric form and the catalytic mechanism. According to our analysis, the high sequence and structural similarity observed among trypanosomatid DHODH suggest that a single strategy of structure-based inhibitor design can be used to validate DHODH as a druggable target against multiple neglected tropical diseases such as Leishmaniasis, Sleeping sickness and Chagas' diseases.
Introduction
The term "Negleted Tropical Diseases (NTDs)" refers to a large and complex group of parasitic and bacterial infectious diseases. They represent one of the most serious burdens to public health, afflicting more than 1 billion people -around one sixth of the world population -most of which live in the poorest and the most marginalized areas of developing countries [1] .
Despite the apparent similarities, the control initiatives and forms of treatment of NTDs are highly heterogeneous. There are effective drugs to treat many of these diseases, available at low cost or donated from pharmaceutical companies, and the control depends on effective eradication programs [1e4] . Nevertheless, there is still a large group of NTDs with no current treatment or depending on old medicines, which cause serious side-effects, have poor clinical effect, and display drug resistance [5, 6] .
One example of this scenario is found for the Leishmaniases, a complex of vector-borne diseases caused by approximately 20 species of obligate intramacrophage parasitic protozoa from the genus Leishmania. Classified as NTDs, the Leishmaniasis affect 12 million men, women and children in 88 countries around the world with approximately 2 million new cases per year [7, 8] . They are manifested in a variety of clinical forms, ranging from cutaneous to visceral leishmaniases, the latter being the most severe and which can be fatal if left untreated. The current treatment for the leishmaniases is mainly based on antimonial derivates of low specificity that result in undesirable side-effects and shows susceptibility to the development of drug resistance [9] .
Although there is an urgent need for the development of better tools to prevent, control and treat Leishmaniases, funding is a critical issue. With only 0.6% of total international development assistance for health allocated to all NTDs, few public resources are available in order to manage and develop new therapeutics to treat this important disease.
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Fortunately, there is increased attention from the research community in the study of the mechanisms related to virulence and pathogenesis of Leishmania which is significantly contributing to the discovery of new leads for diagnostics and drug development [10e13] . Genome sequencing projects of Leishmania major [14] , Leishmania brasiliensis and Leishmania infantum [15] , as well as transcriptomics [16] and proteomics projects [17e19] , are producing data on gene expression profile, protein localization, three-dimensional structure, post-translational modifications, therefore providing a rich source for the understanding the evolution and biology of these pathogens.
Metabolic pathways, which have traditionally provided attractive targets for drug development, are of particular interest [20e22] . As an example, the purine and pyrimidine nucleotide biosynthesis, produced either by de novo biosynthetic or salvage pathways, have already been pointed out as a promising source of drug target candidates [23e25]. In particular, evidence garnered from a variety of parasitic protozoa suggest that the selective inhibition of dihydroorotate dehydrogenase, the fourth enzyme of the de novo pyrimidine biosynthetic pathway, should be considered as an attractive therapeutic target against Leishmaniasis [26e29] .
The enzyme dihydroorotate dehydrogenase (DHODH; E.C, 1.3.3.1) is a flavoenzyme that catalyzes the oxidation of (S)-dihydroorotate to orotate, the only redox reaction in the de novo pyrimidine biosynthesis pathway. On the basis of sequence similarity, the DHODHs are divided in two major classes, i.e., class 1 (A and B) and class 2 [30] . This division correlates with subcellular location of the proteins as well as their preferences for electron acceptors. Enzymes of class 1 are dimeric, located in the cytosol and can be found in Gram-positive bacteria, in the anaerobic yeast Saccharomyces cerevisiae and in all trypanosomatids [26,31e33] . They share less than 20% sequence identity with the monomeric membrane-bound enzymes of class 2, found in the mitochondria of eukaryotes [34] and in some prokaryotes such as the Gramnegative bacteria related to Escherichia coli [35e37]. The cytoplasmic enzymes utilize fumarate or NAD þ to oxidize FMNH 2 , whereas the membrane-bound enzymes require quinones as their physiological oxidizing agent [38] . It is our interest to evaluate the potential of the L. major DHODH (LmDHODH) as a drug target candidate by initially performing a detailed functional characterization of the enzyme. In our previous work, LmDHODH has been kinetically characterized to reduce fumarate to succinate during the oxidation of FMNH 2 to FMN [33] . The reaction catalyzed by LmDHODH occurs by a Ping-Pong BieBi mechanism where the product of the first half reaction (orotate) leaves the active site to allow the entrance of the substrate (fumarate) for the second half reaction. In the present work, we have moved further by focusing the structural studies of LmDHODH. Here, we describe the crystallographic structures of the recombinant LmDHODH crystallized in its apo form (LmDHODH-apo) and complexed with orotate (LmDHODH-oro) and fumarate (LmDHODH-fum) molecules.
Careful analysis of all three structures reveals that both orotate and fumarate molecules occupy the same active site and exploit similar interactions. Furthermore, analysis of LmDHODH structures reveals that rearrangements in the dimeric interface have direct influence on the conformation of the catalytic loop shedding light on the structural role of the dimeric form to regulate the catalytic mechanism of class 1A DHODHs. We further recognized that the high degree of sequence and structural similarity observed among trypanosomatid DHODH suggests that ligands designed to bind LmDHODH can be exploited to validate DHODH as a therapeutic target not only for Leishmaniasis, but also against other trypanosomatid releated diseases, such as Chagas' disease caused by Trypanosoma cruzi and Sleeping Sickness (African trypanosomiasis) caused by Trypanosoma brucei.
Materials and methods

Protein crystallization and X-ray diffraction data collection
Recombinant LmDHODH was expressed in E. coli BL21(DE3) strain and purified to homogeneity by nickel affinity chromatography as described elsewhere [33] . LmDHODH-apo crystals have been previously obtained by the hanging and sitting drop vapordiffusion methods using lithium sulfate as precipitant agent and ammonium sulfate as an additive [39] . Crystals of LmDHODH-oro and LmDHODH-fum complexes were obtained by employing cocrystallization strategies. For LmDHODH-oro complex, purified LmDHODH protein solution was initially dialyzed against 50 mM Hepes pH 7.2 and 150 mM NaCl in presence of 1 mM orotate, and concentrated up to 9.4 mg/mL. For LmDHODH-fum complex, the purified LmDHODH protein solution has been dialyzed against 50 mM Hepes pH 7.2 and 150 mM NaCl, concentrated up to 4 mg/ mL and incubated for 3 h with 5 mM fumarate. Cocrystallization experiments were performed at 293 K by using the sitting drop vapor-diffusion method. Drops were prepared by mixing 2.0 mL of protein solution and 2.0 mL of reservoir solution containing Prior to X-ray data collection, the crystals were transferred to a cryoprotectant solution comprising reservoir solution supplemented with 20% glycerol, and flash-cooled in a nitrogen stream. Data collection for LmDHODH-apo was performed using an inhouse rotating-anode generator [39] . For both LmDHODH-oro and LmDHODH-fum complexes, the data collections were performed at the protein crystallography beamline D03B-MX1 of the Brazilian Synchrotron Light Laboratory (LNLS) using X-rays of wavelength 1.427 Å radiation and recorded on a marCCD165 detector. All three X-ray data sets were collected at 100 K. Diffraction data were [39] . b R sym ¼ P jI obs -<I>j/ P I obs , where < I > is the mean intensity of multiple observations of symmetry-related reflections.
c R work ¼ P h k l jjFoj-jFcjj/ P jFoj, where Fo is the observed structure factor and Fc is the calculated structure factor. d R free is the same as R work except calculated using 5% of the data that are not
included in any refinement calculations. e Distribution of dihedral angles in Ramachandran diagram were calculated with MolProbity program [45] .
indexed and integrated using MOSFLM [40] , and scaled using SCALA [41] . Table 1 summarizes data collections statistics.
Phasing and refinement
The structure of LmDHODH-apo was solved by molecular replacement using the coordinates (excluding the water molecules) of the dimeric structure of Lactococcus lactis DHODH as the search model (PDB code: 1DOR [42] ). Crystals of the two complexes LmDHODH-oro and LmDHODH-fum proved to be isomorphous to LmDHODH-apo crystal previously obtained in the space group P6 1 . Thus, the coordinates of the LmDHODH-apo with waters removed were used to obtain an initial set of phases for both LmDHODH-oro and LmDHODH-fum complexes. The coordinates for the orotate and fumarate molecules and appropriate chemical restraints and topology files were prepared using Hetero-compound Information Center -Uppsala (HIC-Up) server. Waters were built using Coot [43] and validated by hand. The models were initially refined by rigid body refinement, followed by several rounds of model rebuilding using Coot and refinement with REFMAC5 [44] . Table 1 summarizes refinement statistics. The stereochemistry for LmDHODH-apo, LmDHODH-oro and LmDHODH-fum models were validated with Molprobity [45] . All pictures were generated with the PYMOL software [46] .
Protein data bank accession codes
Coordinates and structure factors have been deposited in the PDB with the accession codes 3GYE (LmDHODH-apo), 3GZ3 (LmDHODH-oro), and 3TQ0 (LmDHODH-fum).
Results and discussion
Structure determination
Crystallization, X-ray diffraction data acquisition and initial phasing of LmDHODH in its apo form (LmDHODH-apo) was previously described [39] . LmDHODH-apo crystallized in P6 1 space group using lithium sulfate as the precipitant agent and its crystal structure was solved by molecular replacement using the crystallographic structure of L. lactis DHODH as the search model [42] . A complete dataset to 2.0 Å resolution was used to refine the LmDHODH-apo structure, which consisted of a dimer in the asymmetric unit. Both polypeptide chains (chains A and B) comprises residues from Crystals of LmDHODH-oro and LmDHODH-fum complexes were obtained by cocrystallization techniques. LmDHODH-oro and LmDHODH-fum crystals displayed a high degree of isomorphism related to the LmDHODH-apo, with the same hexagonal symmetry and cell parameter deviation lower than 1%. The refined coordinates of LmDHODH-apo (excluding the solvent molecules) were used for initial rigid body refinement of LmDHODH-oro and LmDHODH-fum structures at 2.5 and 1.9 Å resolution, respectively. The dimeric structure of LmDHODH is very similar to all available models for class 1A DHODHs (Fig. 1 
Binding mode of orotate and fumarate molecules
Orotate and fumarate molecules correspond to the product of catalysis and the oxidant agent for class 1A DHODHs, respectively. Both molecules were clearly present in the active site, as observed by the final s A -weighted 2F o -F c maps for the corresponding complexes (Fig. 2) .
Both orotate and fumarate molecules were found approximately parallel to the isoalloxazine ring. In detail, the pairs of orotate atoms (N1)/(O2) and (N3) (Fig. 4) . The latter two interactions are equivalent to the hydrogen bonds between orotate (O2) and Asn 68 (Nd2) and Ser 196 (Og) from LmDHODH-oro.
Cys 131 which has been previously described to be the catalytic base for class 1A DHODH [30, 49] and is responsible for abstracting a proton from the substrate dihydroorotate (C5) is not present in the LmDHODH-apo and LmDHODH-oro due to the lack of interpretable electron density. In the LmDHODH-fum structure, where the catalytic loop is stabilized, the Cys 131 is located with its S g at distances 3.6 Å, 4.2 Å and 4.3 Å from fumarate C3, C4 and O1A, respectively. Overall, the global structures of the protein molecules in the two cocrystal structures are almost identical. Nevertheless, a notable difference is observed in LmDHODH-fum structure where the activesite loop is found in a closed conformation. Different from LmDHODH-apo and LmDHODH-oro structures where the same region is found disordered, this observation could initially suggest that only fumarate could stabilize the active-site loop in its closed conformation. However, inspection of several crystal structures available for class 1A DHODH in the apo form (1DOR [42] , 2DJX [49] , 3OIX [50] , LmDHODHapo); in complex to orotate (2DOR [47] , 2E6A [49] , 3C61 [data not published], 2B4G [27] , LmDHODH-oro); in complex to fumarate (2E6D [49] , LmDHODH-fum) or even in complex to different ligands (2BSL, 2BX7 [52] , 3C3N [48] , 2E68, 2E6F, 2DJL [49] , 3MJY and 3MHU [53] ) supports the observation that the position of the catalytic loop described for class 1A crystal structures does not intrinsically depend on the occupancy of the active site. For example, in the apo structures the loop is found stabilized in the closed position for 1DOR and 2DJX, whereas for 3OIX the same region is found stabilized in an open conformation and for LmDHODH-apo is found disordered. For DHODH-orotate complexes the loop is commonly found stabilized in found in 3MJY and 3MHU structures are consequence of direct interactions between the ligands and the base of the catalytic loop, suggesting that class 1A inhibitors can explore fumarate and orotate interactions in the active site in order to enhance selectivity and also interfere with loop flexibility to increase potency. In summary, the three-dimensional structures of LmDHODH-oro and LmDHODH-fum, where orotate and fumarate are found to bind to the same active site, are consistent with the previous kinetic characterization which showed that catalysis of LmDHODH is performed by a Ping-Pong BieBi mechanism [32] .
Dimer interface
LmDHODH exists as homodimer both in solution [33] and in the asymmetric unit. The two monomers of LmDHODH are related by a non-crystallographic 2-fold axis with forty-six amino acid residues from each subunit stabilizing the dimer interface. Hydrophobic, hydrophilic and, in particular, stacking interactions play an important role in dimer stability. . This high degree of sequence conservation sheds light on a potential functional role for the dimeric form in class 1A DHODHs. Actually, the relevance of the dimeric form for class 1A DHODH has been previously reported [54] . In their studies, Ottosen and collaborators showed that a dimer dissociation induced by site directed mutagenesis led to the loss of enzymatic activity in L. lactis DHODH. Furthermore, single-molecule studies previously reported have provided evidences for half-sites reactivity in class 1A DHODH, in which only one subunit reacts at a time [55] . In this present model, the dimeric interface could also play an important role in the exchange of information between the two subunits during catalysis.
Interestingly, when the catalytic loop is found stabilized, as only observed in LmDHODH-fum structure, a cavity (200 To further investigate the character of this atom, we estimated the atomic occupancies and temperature factor for different atoms present in the buffers used for protein purification and crystallization. Water molecules, alkali metal cations: Na
, Ni 2þ and the monovalent ions Cl À and NH 4 þ , were evaluated to fit and satisfy both chemical and electron density requirements. Our strategy shows that the binding species are most likely to be Ni 2þ (present during protein purification), although we cannot completely rule out the possibility of coexistence of other species with lower occupancies. As a consequence of the 2-fold axis of the dimer, the Ni 2þ ion has been found to occupy this cavity with double occupancy (Fig. 4) and (Fig. 4) . In addition, the position of the divalent cation is stabilized by the aromatic p-system of Tyr 142 , as a further evidence of the chemical nature of our ligand.
A comparison among LmDHODH-apo, LmDHODH-oro and LmDHODH-fum structures indicates that a conformational change in both His 174 and Asp 171 side chains and a consequent disruption of a hydrogen bond between those two residues can be observed when the divalent cation is found in the dimer interface (Fig. 4) . The range of interactions observed in the LmDHODH-fum complex, are present neither in LmDHODH-apo nor LmDHODH-oro crystal structures, as a consequence of the high flexibility observed for the catalytic loop. Actually, it can be observed that the movement of the region comprising from Leu 129 to Tyr 142 and required for regulating catalysis has a direct influence on the dimeric interface, resulting in dynamic changes in the volume and charge distribution of the cavity where the cation ion has been found. 3OIX, 1JUE, 2BSL, 2BX7, 3C3N and 3C61) . In one particular case, analysis of the high resolution data available for the crystal structure of T. cruzi DHODH in complex to oxonate (PDB ID 2E6F [49] ,) allowed us to unambiguously assign a PEG molecule for remaining electron density found at the dimer interface (supplemental Fig. S1 ). Furthermore, the final s A -weighted 2F o -F c and F o -F c maps for the available structures frequently show remaining spurious density in this region accounting for either low occupancy or high flexible molecules. This promiscuous nature of this binding pocket could be interpreted as a result of extensive hydrophobic contacts as well as a network of polar interactions available on the periphery of the protein surface. , TcDHODH-CLBrener1 (T. cruzi strain CLBrener) and TcDHODH-Tulahuen1 (T. cruzi strain Tulahuen). The sites S1, S2, S3, S4 and S5 are indicated by pink, blue, orange, green and red stars, respectively. The alignment was performed using MULTALIN [57] and graphically displayed using ESPript [58] . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
To date there is no evidence supporting the need of a cation ion or any ligand for the stabilization the dimeric form or for regulating the catalytic activity in class 1A DHODHs. However, as observed in this work, there is a structural relationship between the dimer interface and the conformation of the catalytic loop, suggesting that the binding of specific molecules at the oligomer interface may alter the catalytic properties of class 1A DHODH.
Thus, considering the relevance of the oligomerization state for class 1A DHODH activity [54, 55] , together with the absence of the dimeric interface in class 2 DHODHs, it is of our interest to exploit this binding site for the design of class 1A DHODH selective inhibitors. Site-directed mutagenesis studies are now in progress in order to provide the molecular basis that correlates the dimer interface and protein function.
Trypanosomatid DHODHs and implications for inhibitor design
The genome sequencing projects of trypanosomatid organisms, which include human pathogenic species like T. cruzi [56] , T. brucei [20] and Leishmania species [14, 15] have had a major contribution in the characterization of several genes involved in the parasites' biology. Also, they have allowed the identification of similarities and differences at molecular level of these related species. To date, the genome annotation process has assigned the putative function for DHODH enzyme to gene products of different trypanosomatids and reveals a high degree of sequence identity varying from 73 to 76% when comparing LmDHODH to homologous trypanosoma DHODHs and 83e96% when compared to other Leishmania species (Fig. 6 ). Trypanosomatid DHODH (TrypDHODHs) share around 50e57% of sequence identity when comparing to other members of class 1A DHODHs and 18e27% when comparing to members of class 2 DHODH. In particular, LmDHODH and the homologous human enzyme (HsDHODH) share approximately 25% of sequence identity.
According to our previous work, there are significant differences between TrypDHODHs and the homologous human enzyme that could guide the selection of target sites for drug discovery [48] . By using TcDHODH as a model, topological analysis helped us to identify five different independent regions that display appropriate shape, volume and location to interact with ligands and thus could be exploited for the design of selective ligands against TrypDHODHs [53] . Named according to the distance from the active site, these sites comprise: the active site (S1); an extension of S1 site (S2); the site behind the catalytic loop (S3); an extension of S3 site (S4); and the cavity found at the dimeric interface (S5) (Fig. 5) . Careful analyses of the crystal structures of LmDHODH-apo and LmDHODH-oro described in this work which reveals the lack of electron density from Leu 129 to Tyr 142 have allowed us to estimate the length of the flexible region of the active site loop (b4-aA loop; Fig. 5 ). In addition, the monitoring of the conformation dynamics of the active site loop, which comprises residues from S2, S3 and S5 sites (Fig. 5) , has brought to our attention the plastic character of S2 to S5 pockets of interaction, as well as the different possible routes of accessing the active site, suggesting new possible strategies to be exploited in the design of TrypDHODHs inhibitors. When comparing LmDHODH against all available TrypDHODHs sequences and structures, we found that all sites (S1 to S5) are highly conserved in terms of conformation and chemical nature (Fig. 6) . S1, S3 and S5 sites are found fully conserved and only few substitutions are found at S4 and S2 sites, the later recently validated as a new site of interaction for inhibitor development against class 1A DHODHs [53] . At the S4 site a single mutation can be observed in Leishmania species where the conserved Ile 172 found in T. cruzi and T. brucei DHODHs is replaced by a Phe 172 (Fig. 6) . As a result, S4 site is found to be slightly shallower in Leishmania (Fig. 6 ). The differences in volume, geometry of its side chain at the S2 site and the highly reactive character of this free cysteine residue could drive an alternative route for the design of selective inhibitors covering a large spectrum of Leishmania DHODHs.
Conclusion
We report the determination of the crystal structure of LmDHODH in its apo form and in complex with both orotate and fumarate molecules. Our findings provide a new contribution to the understanding of the mechanism of action of class 1A DHODHs and for the structure-assisted design of inhibitors against LmDHODH. Furthermore, the high sequence and structural similarities observed among trypanosomal DHODHs associated to the intrinsic differences between class 1 and class 2 DHODHs suggests that a single strategy can be used for the development of selective DHODH inhibitors that target multiple trypanosomatid targets. Work is ongoing to validate DHODH as druggable target for multiple neglected tropical diseases such as Leishmaniasis, Sleeping Sickness and Chagas' Diseases.
